Page last updated: 2024-12-05

2-pyrrolidone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-pyrrolidone: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyrrolidin-2-one : The simplest member of the class of pyrrolidin-2-ones, consisting of pyrrolidine in which the hydrogens at position 2 are replaced by an oxo group. The lactam arising by the formal intramolecular condensation of the amino and carboxy groups of gamma-aminobutyric acid (GABA). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12025
CHEMBL ID276849
CHEBI ID36592
MeSH IDM0091749

Synonyms (111)

Synonym
CHEBI:36592 ,
alpha-pyrrolidone
gamma-aminobutyric lactam
alpha-pyrrolidinone
1-azacyclopentan-2-one
gamma-butyrolactam
2-ketopyrrolidine
gamma-aminobutyric acid lactam
pyrrolidon [german]
butanoic acid, 4-amino-, lactam
gamma-aminobutyrolactam
hsdb 2652
nsc 4593
nsc 8413
einecs 210-483-1
ec 210-483-1
kkl5d39eol ,
unii-kkl5d39eol
hydrogen tribromide, compound with pyrrolidin-2-one (1:3)
einecs 245-100-7
nsc-8413
.gamma.-aminobutyric lactam
2-pyrrolidone
butanoic acid, lactam
wln: t5mvtj
pyrrolidon
2-oxopyrrolidine
2-pyrrolidinone
.alpha.-pyrrolidone
butyrolactam
nsc4593
4-aminobutyric acid lactam
nsc8413
.alpha.-pyrrolidinone
2-pyrol
616-45-5
.gamma.-butyrolactam
pyrrolidone
nsc-4593
.gamma.-aminobutyrolactam
NCIOPEN2_000687
inchi=1/c4h7no/c6-4-2-1-3-5-4/h1-3h2,(h,5,6
pyrrolidin-2-one
2-pyrrolidone mfc4 h7 n1 o1
pyrrolidinone
2-pyrrolidinone, 99%
2-pyrrolidinone, >=99%
CHEMBL276849
P0575
2-azacyclopentanone
AKOS000119138
A15700
NCGC00249089-01
cas-616-45-5
dtxcid707246
tox21_303259
NCGC00257072-01
dtxsid8027246 ,
tox21_201630
NCGC00259179-01
2-pyrrolidone [mi]
povidone impurity b [ep impurity]
copovidone impurity a [ep impurity]
pyrrolid-2-one
2-tetrahydropyrrolone
pyrrolidone [mart.]
pyrrolidone [ep monograph]
2-pyrrolidone [hsdb]
fema no. 4829
FG-0424
2-oxo-4-butyrolactam
a-pyrrolidone
2-pyrolidinone
2-pyrrolidin-one
pyrolidine-2-one
2-pyrrolidinon
2-pyrollidinone
pyrollidone
2-oxo-pyrrolidine
pyrollidin-2-one
2pyrrolidinone
azacyclopentan-2-one
pyrrolidine-2-one
2-pyrrolidinone-3,3,4,4,5,5-d6
pyrrolidone-2
.gamma.-aminobutyric acid lactam
soluphor p
mfcd00005270
F0001-1634
2-pyrrolidinone, purum, >=98.0% (gc)
pyrrolidin-2-on
2-pyrrolidone for synthesis
aminobutyrolactam
aminobutyric lactam
2-pyrol4-aminobutyric acid lactam
tetrahydropyrrolone
aminobutyric acid lactam
2-pyrrolidone-butyrolactam
pyrrolidone, european pharmacopoeia (ep) reference standard
pyrrolidin-2-one (2-pyrrolidone)
CS-0019427
HY-Y1831
butyrolactim
Q285640
BCP26683
STL197473
pyrrolidin-2-one (1-aza-2-cyclopentanone)
D96808
EN300-19119
PD078398
Z104472846

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" To describe the time course of the plasma levels of AP and its metabolites after iv administration, a pharmacokinetic model with seven compartments was applied, which included 10 first-order rate constants and one Michaelis-Menten constant."( Pharmacokinetics of aniracetam and its metabolites in rats.
Horibe, Y; Ikeda, K; Iwaki, M; Ogiso, T; Paku, T; Suzuki, H; Tanino, T, 1998
)
0.3

Bioavailability

ExcerptReferenceRelevance
" Elimination of AP and ABA was rapid after oral dosing, and the bioavailability of AP was extremely small (11."( Pharmacokinetics of aniracetam and its metabolites in rats.
Horibe, Y; Ikeda, K; Iwaki, M; Ogiso, T; Paku, T; Suzuki, H; Tanino, T, 1998
)
0.3
" Collected results suggest that the proposed one-pot process can be used to prepare polymer based composites to increase bioavailability of low solubility drugs without utilization of toxic solvents and under mild temperature conditions."( A one-pot method to enhance dissolution rate of low solubility drug molecules using dispersion polymerization in supercritical carbon dioxide.
Filardo, G; Galia, A; Scialdone, O; Spanò, T, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
polar solventA solvent that is composed of polar molecules. Polar solvents can dissolve ionic compounds or ionisable covalent compounds.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrrolidin-2-onesA pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
phosphopantothenate biosynthesis II011
phosphopantothenate biosynthesis II012

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency49.05200.006038.004119,952.5996AID1159521
SMAD family member 2Homo sapiens (human)Potency55.51960.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency55.51960.173734.304761.8120AID1346859
AR proteinHomo sapiens (human)Potency24.73550.000221.22318,912.5098AID1259243; AID1259247; AID1259381
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency24.33650.000657.913322,387.1992AID1259377
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency13.06360.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency28.70580.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency69.28770.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency48.76800.000229.305416,493.5996AID743075; AID743079
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency43.27710.001723.839378.1014AID743083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.505710.0000AID71829
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.497310.0000AID71829
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.498810.0000AID71829
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.504610.0000AID71829
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.506510.0000AID71829
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.505710.0000AID71829
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)435,000.00000.00010.507510.0000AID71829
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Olfactory receptor 51E2Homo sapiens (human)EC50 (µMol)0.00190.00000.07800.5700AID1639697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
adenylate cyclase-activating G protein-coupled receptor signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
cell migrationOlfactory receptor 51E2Homo sapiens (human)
melanocyte differentiationOlfactory receptor 51E2Homo sapiens (human)
steroid hormone mediated signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
positive regulation of blood pressureOlfactory receptor 51E2Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of smellOlfactory receptor 51E2Homo sapiens (human)
cellular response to fatty acidOlfactory receptor 51E2Homo sapiens (human)
melanocyte proliferationOlfactory receptor 51E2Homo sapiens (human)
positive regulation of renin secretion into blood streamOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nuclear steroid receptor activityOlfactory receptor 51E2Homo sapiens (human)
G protein-coupled receptor activityOlfactory receptor 51E2Homo sapiens (human)
olfactory receptor activityOlfactory receptor 51E2Homo sapiens (human)
signaling receptor activityOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
early endosome membraneOlfactory receptor 51E2Homo sapiens (human)
intracellular organelleOlfactory receptor 51E2Homo sapiens (human)
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID140740Sleeping time in mice after administration in mice induced by sodium pentobarbital1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID225513Effective dose required for anticonvulsive activity in maximal electroshock seizure (MES) test; Not effective2000Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7
Design and synthesis of anticonvulsive agents as gamma-vinyl GABA-based potential dual acting prodrugs and their biological activities.
AID22273Degradation rate constant in biological media of rat plasma homogenates.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID225520Anticonvulsive activity in picrotoxin (PCR) induced seizure test (ineffective)2000Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7
Design and synthesis of anticonvulsive agents as gamma-vinyl GABA-based potential dual acting prodrugs and their biological activities.
AID22274Degradation rate constant in the buffer solution(pH 7.4) was studied as a measure of the stability of the compound.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID139780Onset for sleeping time after administration in mice induced by sodium pentobarbital1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID23728Apparent partition coefficient between 1-octanol and pH 5.0 phosphate buffer (0.1 M) at 37 degrees Centigrade.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID22272Degradation rate constant in biological media of rat liver homogenates.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID70688Percentage of benzidine-positive murine erythroleukemia cells on day 6.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID136515Latency to the onset of generalized clonic epileptic seizures by picrotoxin was measured and evaluated as a percent of the control in mice.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID225510Effective dose required for anticonvulsive activity in bicuculline (BIC) test; Not effective2000Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7
Design and synthesis of anticonvulsive agents as gamma-vinyl GABA-based potential dual acting prodrugs and their biological activities.
AID70689Cell growth was measured on day 3, after murine erythroleukemia cells were exposed at a cell concentration of 1*10e5 cells/mL.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID25749Compound was evaluated for the second order hydrolysis rate constant2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Hydrolytic stability versus ring size in lactams: implications for the development of lactam antibiotics and other serine protease inhibitors.
AID1082888Nematicidal activity against Meloidogyne incognita (root-knot nematode) juveniles J2 assessed as paralysis after 1 day2012Journal of agricultural and food chemistry, Aug-01, Volume: 60, Issue:30
Nematicidal activity of 2-thiophenecarboxaldehyde and methylisothiocyanate from caper (Capparis spinosa) against Meloidogyne incognita.
AID225515Effective dose required for anticonvulsive activity in pentylenetetrazole (PTZ) test at >0.1 mmol/kg2000Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7
Design and synthesis of anticonvulsive agents as gamma-vinyl GABA-based potential dual acting prodrugs and their biological activities.
AID19839Partition coefficient (logP)1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
X-ray crystal structure, partitioning behavior, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore.
AID136516Latency to the protection against lethality by picrotoxin was measured and evaluated as a percent of the control in mice.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID20537Solubility in pH 5.0 phosphate buffer (0.1 M) at 37 degrees Centigrade; Miscible1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID234828Survival ratio was calculated for determination of dose dependency.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID113781Anticonvulsant activity in mice against maximal electroshock (MES) induced tonic hindlimb seizures1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents.
AID70690Cell growth was measured on day 6 after murine erythroleukemia cells were exposed at a cell concentration of 1*10e5 cells/mL.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID22269Degradation rate constant in biological media of mouse brain homogenates.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID71829Binding affinity for Gamma-aminobutyric acid A receptor from rat brain in the presence of radioligand [35S]- TBPS1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents.
AID122003Neurotoxicity in mice was assessed by rotarod test1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents.
AID15691Calculated partition coefficient (clogP)1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
X-ray crystal structure, partitioning behavior, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore.
AID113782Anticonvulsant activity in mice against pentylenetetrazole (PTZ) induced clonic seizures1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents.
AID28486Second-order rate constant (M-1 s-1) for the alkaline hydrolysis in water at 30 degrees C2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Acylating agents as enzyme inhibitors and understanding their reactivity for drug design.
AID22271Degradation rate constant in biological media of rat brain homogenates.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID22270Degradation rate constant in biological media of mouse liver homogenates.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID70691Concentration producing the maximum percentage of benzidine-positive cells after 6-days of continuous exposure in murine leukemia cells.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID1082889Nematicidal activity against Meloidogyne incognita (root-knot nematode) juveniles J2 assessed as paralysis after 1 hr2012Journal of agricultural and food chemistry, Aug-01, Volume: 60, Issue:30
Nematicidal activity of 2-thiophenecarboxaldehyde and methylisothiocyanate from caper (Capparis spinosa) against Meloidogyne incognita.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (128)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (15.63)18.7374
1990's13 (10.16)18.2507
2000's30 (23.44)29.6817
2010's51 (39.84)24.3611
2020's14 (10.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.35 (24.57)
Research Supply Index4.91 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index138.61 (26.88)
Search Engine Supply Index2.69 (0.95)

This Compound (62.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.75%)5.53%
Reviews2 (1.49%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other131 (97.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]